Very down beat - and it was no surprise that staff costs equalled expenditure on research - totally over $500k for the qurter (and just $800k in the piggy bank.
Also, the only real emphasis i with C14 - last gasp effort to try and save the company. The current focus of the Company is on working with C14 to achieve commercial outcomes to its antiviral programs. During 2024 Biotron reported results from three Phase 2 clinical trials, and the data from these trials together with data from the Company’s preclinical programs are central to current commercialisation activities.
The end is not far off I fear.
BIT Price at posting:
1.5¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)